Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AZD7798

Phase 2Small molecule

AZD7798 is one of 51 small molecule programs targeting Crohn's Disease. It is currently in Phase 2.

2

Indications

5

Total Trials

3

Active Trials

50

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseActive, not recruiting

Moderate to Severe Crohn's DiseaseActive, not recruiting

Crohn's DiseasePhase 2

Active, not recruiting

Moderate to Severe Crohn's DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

67 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Entyvio

Humira

RRanbaxy Laboratories Limited

Omvoh

Trexall

Jazz Pharmaceuticals

Epidiolex

Jazz Pharmaceuticals

Opzelura

Mycobutin

Calciferol

Jazz Pharmaceuticals

Levulan

Sun Pharmaceutical Industries, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Moderate to Severe Crohn's Disease

NCT06450197

Q3 2027

Phase 2Active, not recruiting

Crohn's Disease

NCT06681324

Clinical

Trials by Indication[1]

Crohn's Disease4 trials

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06432764·9 enrolled

AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05452304·112 enrolled

Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06053424·13 enrolled

Show 1 more trial

A Participant- and Investigator-blind, Randomized, Placebo-controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair With AZD7798 in Patients With Active Ileal Crohn's Disease and an Ileostomy (CALLISTO)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06681324·24 enrolled

Moderate to Severe Crohn's Disease1 trial

A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06450197·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AZD7798. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD7798 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD7798. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Related News